NESS-040C5

Source: Wikipedia, the free encyclopedia.
NESS-040C5
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
JSmol)
SMILES
  • CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2

NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]

See also

References

  1. ^ Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
  2. PMID 20166928
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=NESS-040C5&oldid=1268765321"